Nachrichten zur Bristol-Myers Squibb Co. Aktie

BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?

Bristol Myers Squibbs Growth Portfolio and pipeline support momentum, but generic headwinds and recent gains call for a cautious stance.…

Schrödinger outlines 10%-15% 2026 ACV growth as Bristol Myers Squibb deploys Bunsen

…

AstraZeneca-BMY megadeal talk sparks huge market rift

Two of the worlds biggest drugmakers moved in opposite directions on Monday, and the split says a lot about how…

AstraZeneca Investors See Little Logic in Bristol Tie-Up

AstraZeneca Plc investors had a clear message for the UK drugmaker on Monday: they don’t like the idea of a $400…

Bristol-Myers Squibb and AstraZeneca said to discuss megamerger

Bristol-Myers Squibb and AstraZeneca said to discuss megamerger - can it happen?…

Stocks making the biggest moves premarket: Alibaba, Bristol-Myers Squibb, eBay & more

These are the stocks posting the largest moves premarket.…

Analysts baffled by AstraZenecas interest in Bristol Myers Squibb

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 6% to 11,872p on Monday, the steepest decline in the FTSE 100, as analysts struggled…

Analysts baffled by AstraZenecas interest in Bristol Myers Squibb

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 6% to 11,872p on Monday, the steepest decline in the FTSE 100, as analysts struggled…

AstraZeneca shares slide 7% on talks to buy Bristol Myers Squibb

Shares in AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) fell 7% to 11,723p on Monday after news that Britains biggest drugmaker is in talks…

AstraZeneca shares slide 7% on talks to buy Bristol Myers Squibb

Shares in AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) fell 7% to 11,723p on Monday after news that Britains biggest drugmaker is in talks…

Morgan Stanley uncovers major Bristol Myers stock signals

Bristol Myers Squibb (BMY) just gave investors a strong quarter and a bigger outlook. Morgan Stanley read the same report…

Pharma: Astra-Zeneca erwägt offenbar 400-Milliarden-Fusion mit US-Rivalen Bristol-Myers Squibb

Der Zusammenschluss wäre eine der größten Fusionen in der Wirtschaftsgeschichte. Ob es zu einem Deal kommt, ist jedoch noch offen.…

AstraZeneca shares slide 7% after reports of Bristol Myers talks

AstraZenecas shares fell sharply on Monday as analysts and investors questioned the logic of a possible tie-up with Bristol Myers…

FTSE 100 Live: Blue-chips to start August on front foot, AstraZeneca merger talks reported

7.47am: AstraZeneca in talks over $400 billion mega-merger AstraZeneca is in talks with Bristol Myers Squibb over a potential merger to…

JPMorgan belässt Astrazeneca auf Overweight - Ziel 16000 Pence

NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Astrazeneca auf "Overweight" mit einem Kursziel von 16000…

Bristol Myers Squibb Isnt Nearly as Cheap as It Looks -- Heres the 1 Thing That Could Change That

Bristol Myers Squibbs P/E ratio is below the industry average, but you have to take this key fact into consideration…

Why Bristol Myers Squibb Stock Topped the Market on Thursday

It notched convincing beats on analyst estimates with its second-quarter performance.…

Bristol-Myers Squibb Company (BMY) Q2 2026 Earnings Call Transcript

…

Israel "Izzy" Englander Increased His Position in This Pharma Stock by 780%. Does He Know Something Wall Street Doesnt?

Analysts arent nearly as bullish about Bristol Myers Squibb as this billionaire hedge fund manager is.…

Bristol Myers Squibb – Der US-Pharmariese rüstet mit NVIDIAs neuestem KI-Supercomputer die Medikamentenforschung auf!

Bristol Myers Squibb kauft als erster Life-Sciences-Konzern einen Nvidia-Supercomputer der neuen Vera-Rubin-Generation für die KI-gestützte Medikamentenforschung. Der Konzern verkürzt die…

Why the Market Dipped But Bristol Myers Squibb (BMY) Gained Today

Bristol Myers Squibb (BMY) reached $60.48 at the closing of the latest trading day, reflecting a +2.99% change compared to…

Is Bristol Myers Squibbs 4.3% Dividend Yield Safe? Heres What Investors Need to Know.

This big pharma stock looks attractive for income investors -- but it comes with some risk.…

House committee investigates Merck, AbbVie over China trials

Five of the biggest names in American pharma just got a deadline from Washington. The House Select Committee on China…

Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Bristol Myers Squibb trades at a deep discount, while Johnson & Johnson boasts higher margins and a broader reach. How…

Heres Why Bristol Myers Squibb (BMY) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note

The latest trading day saw Bristol Myers Squibb (BMY) settling at $55.53, representing a +1.52% change from its previous close.…

ORMP: View Inclusion in Russell Indexes as Positive That Could Raise Awareness in Investment Community

By M. MarinNASDAQ: ORMPREAD THE FULL ORMP RESEARCH REPORTORMP shares to be added to the Russell 2000® & Russell 3000®As…

How Safe is Bristol Myers Squibbs Dividend? Heres My Honest Take.

Bristol Myers Squibb has a well-above-market yield of 4.5% and it appears reasonably safe.…

Why Bristol Myers Squibb (BMY) Outpaced the Stock Market Today

Bristol Myers Squibb (BMY) closed at $56.87 in the latest trading session, marking a +2.28% move from the prior day.…

ORMP: Strategically Acquiring Interests in Medtech & Technology Companies

By M. MarinNASDAQ: ORMPREAD THE FULL ORMP RESEARCH REPORTStrategically acquiring controlling interests in portfolio of companiesOramed Pharmaceuticals (NASDAQ: ORMP) is…

Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know

In the latest trading session, Bristol Myers Squibb (BMY) closed at $57.27, marking a +1.18% move from the previous day.…

Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study

Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.…

Bristol Myers vs. Pfizer: Which High?Yield Dividend Stock Wins Now?

Whichever one you choose, youll need patience before you can see solid returns.…

BioNTech mit neuen Daten – doch reicht das?

BioNTech und der Partner Bristol Myers Squibb haben am Wochenende auf dem ASCO-Meeting in Chicago neue Zwischenergebnisse der Phase-2/3-Studie ROSETTA-Lung-02…

GNW-News: Globale Daten der ROSETTA Lung-02-Studie: Ermutigende Wirksamkeit für BioNTechs und Bristol Myers Squibbs bispezifischen PD-L1xVEGF-A-Immunmodulator-Kandidat Pumitamig bei nicht-kleinzelligem Lungenkrebs

^* Erster bispezifischer PD-(L)1xVEGF-Immunmodulator-Kandidat, zu dem globale Daten mit ermutigender Wirksamkeit in Kombination mit Chemotherapie in der…

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

BioNTech and BMS PD-L1xVEGF-A bispecific pumitamig shows encouraging efficacy in patients with non-small cell lung cancer in ROSETTA Lung-02 trial…

UBS reiterates Bristol-Myers Squibb stock rating on pipeline potential

UBS reiterates Bristol-Myers Squibb stock rating on pipeline potential…

Looking to Buy Bristol Myers Squibb Stock on the Dip? Read This First.

The numbers dont tell the full story with this big pharma stock.…

Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration

U.S. drugmaker Bristol Myers Squibb inked a partnership with a Chinese company that some say could mark the next wave…

Bristol-Myers Squibb Company (BMY) Presents at Bank of America Global Healthcare Conference 2026 Transcript

…

Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors.

This may be an excellent deal for those focused on the long game.…

IgG4-Related Disease Market Analysis and Forecasts, 2025-2026 & 2035 with Amgen, Zenas BioPharma, Bristol Myers Squibb, and Sanofi Leading

Global IgG4-related disease market sees growth due to increased research funding and development of targeted therapies. This rare autoimmune condition…

dpa-AFX ProFeed